Related Experiment Videos
Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear
Antonio H Iglesias1, Sandra Camelo, Daehee Hwang
1Laboratory of Transcriptional and Immune Regulation, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA 02139, USA.
Journal of Neuroimmunology
|April 15, 2004
Summary
Microarray analysis reveals immune cell activation and E2F pathway enhancement in multiple sclerosis (MS) patients. This finding was validated in an animal model, suggesting PBMC microarrays can reflect MS disease processes.
Area of Science:
- Immunology
- Neuroscience
- Genetics
Background:
- Multiple Sclerosis (MS) is a complex autoimmune disease affecting the central nervous system.
- Understanding the molecular mechanisms underlying MS pathogenesis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the molecular profile of peripheral blood mononuclear cells (PBMCs) in multiple sclerosis (MS) patients.
- To explore the role of the E2F pathway in MS.
- To validate findings using an experimental autoimmune encephalomyelitis (EAE) mouse model.
Main Methods:
- Microarray analysis of PBMCs from MS patients.
- Induction of experimental autoimmune encephalomyelitis (EAE) in E2f1-deficient mice.
- Analysis of gene expression related to the E2F pathway and MS susceptibility.
Main Results:
- A distinct molecular profile in MS patient PBMCs, including immune cell activation, autoantigen upregulation, and enhanced E2F pathway transcription.
- E2f1-deficient mice showed only mild disability in the EAE model.
- Avonex treatment in MS patients correlated with lower expression of E2F target genes.
- The identified PBMC profile was enriched in genes associated with MS susceptibility loci and polymorphisms.
Conclusions:
- PBMC microarray analysis can effectively reflect the pathobiology of multiple sclerosis.
- The E2F pathway plays a role in MS pathogenesis and may be a therapeutic target.
- The EAE model serves as a valid platform for validating MS-related molecular findings from human studies.